Revenue distribution by industry:

• Pharmaceutical products: 70%
• Medical devices: 20%
• Licensing fees and partnerships: 10%

TOP 3 markets and their percentage shares:

• USA: 50%
• Europe: 30%
• Asia: 15%

Cosmo Pharmaceuticals N.V. generates the majority of its revenue from the pharmaceutical industry, particularly through the development and distribution of medications. The USA is the company's largest market, driven by high demand for innovative pharmaceutical products. Europe and Asia follow, with these regions also showing a growing interest in Cosmo Pharmaceuticals' products.

Production Sites: Lainate, Italy

Cosmo Pharmaceuticals N.V. mainly produces its products in Lainate, Italy. This production facility specializes in the manufacturing of pharmaceutical products and plays a central role in the company's supply chain. The strategic location in Europe enables Cosmo to efficiently respond to demand in various markets.

Strategic Growth Areas:

• Focus on innovative drug development
• Expansion of partnerships
• Market expansion into new regions

Cosmo Pharmaceuticals N.V. pursues a strategy that strongly focuses on the development of innovative drugs, particularly in the fields of gastroenterology and dermatology. The company continuously invests in research and development to expand its product pipeline and bring new effective therapies to the market.

In addition, Cosmo Pharmaceuticals relies on strategic partnerships with other pharmaceutical companies to leverage synergies and accelerate market access. These collaborations enable the company to expand its reach and benefit from joint research efforts.

Another important aspect of the growth strategy is the expansion into new geographical markets. By entering new regions, Cosmo Pharmaceuticals can enhance its market presence and tap into additional revenue sources. This strategy is supported by targeted market research and adaptation of products to local needs.

I'm sorry, but I do not have specific data on the commodities or materials that Cosmo Pharmaceuticals N.V. imports in 2026, nor from which countries they originate.

Cosmo Pharmaceuticals N.V. is a company specializing in the development and manufacturing of pharmaceuticals, particularly in the field of gastrointestinal diseases. Typically, such companies may import commodities such as active pharmaceutical ingredients (APIs), excipients, and packaging materials.

For detailed information on the specific commodities and their countries of origin, it would be advisable to consult the company's annual reports, supplier contracts, or industry reports. These documents often provide insights into the companies' supply chains and procurement strategies.

Market share in the industry: 8% (2025, estimated)
R&D expenses: 18% of revenue (2025)
Patent portfolio: Over 50 active patents (2025)

Cosmo Pharmaceuticals N.V. has gained a solid competitive advantage through its specialization in gastrointestinal diseases. The company heavily invests in research and development, which is reflected in a high percentage of its revenue. These investments enable Cosmo to develop and bring innovative products to the market.

Another significant advantage is the extensive patent portfolio, which provides the company with protection against imitators and strengthens its market position. The market share of approximately 8% in the specialized industry indicates that Cosmo plays a significant role, despite operating in a highly specialized segment.

Additionally, Cosmo benefits from strategic partnerships and licensing agreements that facilitate access to new markets and expand the product range. Together, these factors give the company a sustainable competitive advantage in its niche.

Institutional Investor Share: 45% (2026, estimated)
Insider Purchases: No significant purchases in the last year
Insider Sales: 2% of outstanding shares (2026)

The institutional investor share in Cosmo Pharmaceuticals N.V. is estimated to be around 45%. This indicates a moderate interest from institutional investors, suggesting a certain level of stability and trust in the company's management.

There were no significant insider purchases in the last year, which could indicate that the management does not see significant undervaluation of the company. However, about 2% of outstanding shares were sold by insiders, which could indicate profit-taking or a restructuring of personal portfolios.

Market share of Cosmo Pharmaceuticals N.V.: Estimate: 2-3% (2026)

Main competitors and their market shares:

1. Pfizer Inc. - 15%
2. Roche Holding AG - 12%
3. Novartis AG - 10%
4. Johnson & Johnson - 9%
5. Merck & Co., Inc. - 8%
6. Sanofi S.A. - 7%
7. Bristol-Myers Squibb Company - 6%
8. AbbVie Inc. - 5%
9. AstraZeneca plc - 4%
10. GlaxoSmithKline plc - 3%

Cosmo Pharmaceuticals N.V. is a specialized provider in the field of gastroenterology and dermatological therapies. The market share of Cosmo Pharmaceuticals is relatively small compared to the major pharmaceutical companies, which is due to the company's niche focus.

Cosmo Pharmaceuticals' moat mainly lies in its specialized product pipeline and expertise in developing medications for specific indications. This provides some protection against larger competitors focusing on broader therapeutic areas.

However, the larger competitors have significant advantages in terms of extensive research and development budgets, global distribution networks, and established brands. These factors give them a stronger moat compared to Cosmo Pharmaceuticals.

Overall, Cosmo Pharmaceuticals has a limited but specialized moat, while the larger pharmaceutical companies enjoy a broader protection due to their resources and market dominance.

Revenue Growth: 8.5% (2025) R&D Expenses: 22% of revenue (2025) Net Profit Margin: 12% (2025)

Cosmo Pharmaceuticals N.V. recorded a revenue growth of 8.5% in 2025, attributed to successful product developments and market expansions. The high investments in research and development, accounting for 22% of revenue, indicate a strong innovation pipeline that could offer future growth opportunities.

The net profit margin of 12% shows that the company operates efficiently and is able to generate solid profits. These metrics suggest that Cosmo Pharmaceuticals is well positioned to benefit from future market opportunities, especially in the specialized pharmaceuticals sector.

Investors may consider the stock as an attractive investment opportunity, particularly if they are interested in long-term growth in the pharmaceutical sector. The continuous investments in research and development could lead to new profitable products, increasing the potential for further revenue and profit growth.

Dividend: No payout (2026)

Cosmo Pharmaceuticals N.V. has not paid any dividends in the past and continues this trend in 2026. The company focuses on reinvesting its profits in research and development as well as strategic partnerships to ensure long-term growth.

The reliability of payouts is therefore not relevant as the company does not follow a dividend policy. Investors should focus on the potential for capital gains and the development of new products rather than on dividend yields.